Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q3 FY25 results · Oct–Dec 2024
Panacea Biotec reported revenue from operations of ₹163.49 crore (up 8.6% from Q3 FY24) and net profit of ₹4.44 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 163.49 | 150.50 | +8.6% | 147.35 | +11.0% |
| Other income | 3.62 | 5.68 | −36.3% | 4.65 | −22.2% |
| Total income | 167.11 | 156.18 | +7.0% | 152.00 | +9.9% |
| Profit before tax | 4.38 | (1.65) | Turned profit | 4.76 | −8.0% |
| Net profit for the period | 4.44 | (2.20) | Turned profit | 4.71 | −5.7% |
| Attributable to shareholders of the company | 4.52 | — | — | 4.80 | −5.8% |
| EPS, basic (₹) | 0.74 | (0.37) | Turned profit | 0.77 | −3.9% |
| Net margin (%) | 2.7 | -1.5 | 3.2 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 108.43 | 95.23 | +13.9% | 76.64 | +41.5% |
| Other income | 3.32 | 3.05 | +8.9% | 3.41 | −2.6% |
| Total income | 111.75 | 98.28 | +13.7% | 80.05 | +39.6% |
| Profit before tax | 9.65 | 1.07 | +801.9% | 1.30 | +642.3% |
| Net profit for the period | 9.65 | 0.43 | 22x | 1.29 | +648.1% |
| EPS, basic (₹) | 1.58 | 0.07 | 23x | 0.21 | +652.4% |
| Net margin (%) | 8.9 | 0.5 | 1.7 |
Consolidated
- Filed with BSE
- 14 Feb 2025, 19:14 IST
- Board meeting
- 14 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Feb 2025, 19:14 IST
- Board meeting
- 14 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE